toxic epidermal necrolysis
Pharmigene said last week that 50 hospitals in Taiwan will now administer its test for HLA-B*1502, which is a marker for increased risk of adverse events in Asian populations treated with the anti-seizure drug carbamazepine.
Pharmigene Licenses IP to Mayo Clinic for Companion Dx for Stevens-Johnson Syndrome
The Mayo Clinic will develop tests to detect for the presence of alleles that increase the risk for developing the potentially deadly skin disease if certain drugs are taken.
Serious Adverse Events Consortium Releases First Data Set on Genes Linked to Stevens-Johnson Syndrome
The data, analyzed from biological samples donated by GlaxoSmithKline, is available on SAEC's website for free, and the group plans to publish the associations later this year. However, an SAEC official said "it would be preliminary to develop a meaningful diagnostic chip off this data."